Bioassays in Allergy: Technical Characteristics, Limitations, and Pathways to Clinical Implementation—An EAACI Position Paper
Abstract
Bioassays offer functional readouts of immune responses through specific biomarkers, providing mechanistic insight beyond conventional serology. By capturing cellular activation, tissue‐level changes, and molecular signaling, they hold promise for refining allergy diagnosis, risk stratification, and treatment monitoring, contributing to precision medicine. This review summarizes the current landscape of three allergy‐relevant bioassays: basophil activation test, histology, and molecular biology‐based assays. We discuss their underlying principles, clinical utilities as well as methodological and translational challenges and translational barriers. Attention is given to unmet needs such as assay standardization, reproducibility, and integration into clinical workflows. Finally, we outline future directions for research and clinical implementation, emphasizing the potential of bioassays to refine personalized management of allergic disorders. This position paper clearly distinguishes between descriptive summaries of the available evidence and the potential applicability recommendations of the EAACI Task Force, thereby enhancing clarity and interpretability for clinicians and researchers.
Related
- Photostimulus intensity, rather than colour or polarization, is the key driver for stable fly visual attraction in laboratory bioassays
- The factors affecting the success of the artificial insemination of bumblebees and technical improvements
- Editorial: Advances in molecular diagnostics of allergy: novel allergens, biomarkers, and technical developments
- Limitations of Genomic Foundation Models for Decoding Regulatory Mechanisms in ALS
- Promises and limitations of current ancient human epigenetic clocks
BibTeX
@article{karaaslan2026bioassays,
title = {{Bioassays in Allergy: Technical Characteristics, Limitations, and Pathways to Clinical Implementation—An EAACI Position Paper}},
author = {Cagatay Karaaslan and Oscar Palomares and Busra Kilic and Cristobalina Mayorga and Hans Jürgen Hoffmann and Bernadette Eberlein and Edward Knol and Ruben Fernandez-Santamaria and Joana Vitte and Elena Izquierdo and Cristina Gomez-Casado and Marina Perez-Gordo and Araceli Diaz Perales and Maria Escribese},
journal = {Clinical and Translational Allergy},
year = {2026},
month = sep,
doi = {10.1002/clt2.70210},
url = {https://univ-reims.hal.science/hal-05783012v1},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Bioassays in Allergy: Technical Characteristics, Limitations, and Pathways to Clinical Implementation—An EAACI Position Paper
AU - Cagatay Karaaslan
AU - Oscar Palomares
AU - Busra Kilic
AU - Cristobalina Mayorga
AU - Hans Jürgen Hoffmann
AU - Bernadette Eberlein
AU - Edward Knol
AU - Ruben Fernandez-Santamaria
AU - Joana Vitte
AU - Elena Izquierdo
AU - Cristina Gomez-Casado
AU - Marina Perez-Gordo
AU - Araceli Diaz Perales
AU - Maria Escribese
PY - 2026
DA - 2026/09/30
JO - Clinical and Translational Allergy
DO - 10.1002/clt2.70210
UR - https://univ-reims.hal.science/hal-05783012v1
AB - Bioassays offer functional readouts of immune responses through specific biomarkers, providing mechanistic insight beyond conventional serology. By capturing cellular activation, tissue‐level changes, and molecular signaling, they hold promise for refining allergy diagnosis, risk stratification, and treatment monitoring, contributing to precision medicine. This review summarizes the current landscape of three allergy‐relevant bioassays: basophil activation test, histology, and molecular biology‐based assays. We discuss their underlying principles, clinical utilities as well as methodological and translational challenges and translational barriers. Attention is given to unmet needs such as assay standardization, reproducibility, and integration into clinical workflows. Finally, we outline future directions for research and clinical implementation, emphasizing the potential of bioassays to refine personalized management of allergic disorders. This position paper clearly distinguishes between descriptive summaries of the available evidence and the potential applicability recommendations of the EAACI Task Force, thereby enhancing clarity and interpretability for clinicians and researchers.
SN - 2045-7022
ER -